Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 18/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20915385 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL20936519 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL20915371 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL21449551 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL20915198 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL20915256 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL22273360 | 1.00 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL22402405 | 0.87 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL20654871 | 0.87 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL19888575 | 0.87 | PLA2G2A (0.40) | PLA2G2AEPHX2PLA2G10PLA2G1BPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | Epitracker, Inc. | 2021-12-16 | — | — | US | disclosed |
| US-20200345676-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2020-11-05 | — | — | US | disclosed |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | Epitracker, Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | Epitracker, Inc. | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117607-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | PLA2G2A 1942/4885EPHX2 3189/4885PLA2G10 2614/4885 |
| US-20210386710-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAIN | SCD, FABP7, ELOVL1 | PLA2G2A 1156/4885EPHX2 1687/4885PLA2G10 1276/4885 |
| US-10792266-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | PLA2G2A 1942/4885EPHX2 3189/4885PLA2G10 2614/4885 |
| US-11951088-B2 | Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome | FABP1, FASN, GPR119 | PLA2G2A 1942/4885EPHX2 3189/4885PLA2G10 2614/4885 |
| US-20200345676-A1 | FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF CONDITIONS RELATED TO METABOLIC SYNDROME | FABP1, FASN, GPR119 | PLA2G2A 1942/4885EPHX2 3189/4885PLA2G10 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.